Rentokil Initial shares tumbled as much as 20% in a single session, making it one of the worst days in recent memory for the FTSE 100 pest control giant.
The sell-off came despite first-half revenue rising 6.7% and adjusted operating profit climbing 6.6%, numbers that would ordinarily satisfy most investors in any market.
Instead, traders focused on three uncomfortable details buried within the results that pointed to deeper structural challenges in the group’s most important market.
North America organic growth slowed to 2.4% in the second quarter, down from 2.8% in the first quarter and well behind the firm’s own 3% target.
Adding to the concern, rival Rollins posted roughly 5.7% organic growth over the same period, suggesting Rentokil is losing competitive ground rather than simply battling a tough trading environment.
Management also retired its 2027 target of a 20% North America operating margin, choosing instead to prioritise investment in volume growth over near-term profitability.
The broader FTSE 100 was in celebratory mood on the same day, hitting a fresh all-time high above 10,950 on the back of strong results from Rolls-Royce and Shell, making Rentokil’s decline all the more stark.
On valuation grounds, the stock now trades on a forward price-to-earnings ratio of around 19, which looks attractive for a leading business operating in a highly resilient and largely recession-resistant industry.
The balance sheet has improved notably, with the firm’s leverage ratio dropping back to 2.4, in line with its long-term target following the debt burden accumulated after a major acquisition in recent years.
New chief executive Mike Duffy’s comments suggest he believes a North America growth recovery is a matter of months rather than years, offering some reassurance to investors with patience.
The long-term investment case for Rentokil rests on pest control being an acyclical, recession-resistant business in a growing market, with climate change widely seen as a structural tailwind for demand.
Rentokil remains the largest pest control operator globally by a wide margin, and scale matters enormously in a route-density business where efficiency compounds over time.
The critical question for investors is not whether North American margins recover, but when, and whether revenue growth in the interim can compensate for the ongoing compression.
For those already holding shares, the short-term pain is real, but the case for staying invested remains grounded in the company’s market position and improving financial discipline.